Inga Galuba

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Reversible-covalent Inhibitor, Molecular Pharmacology, Signaling Pathway +19

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

Alexei S. Karpov, Payman Amiri, Cornelia Bellamacina et al. · ACS Medicinal Chemistry Letters · 2015 · 102 citations · Full text

Drug Target, Molecular Biology, Pharmacotherapy +16

2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4

Thomas Knoepfel, Pascal Furet, Robert Mah et al. · ACS Medicinal Chemistry Letters · 2018 · 42 citations · Full text

Molecular Docking, Molecular Pharmacology, Medicinal Chemistry +15

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region

Robin A. Fairhurst, Thomas Knoepfel, Catherine Leblanc et al. · MedChemComm · 2017 · 38 citations · Full text

Drug Target, Bioorganic Chemistry, Cell Growth +23

Association of Time to Recurrence With Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression in Stage II and III Colorectal Cancer

Marko Kornmann, Karl H. Link, Inga Galuba et al. · Journal of Gastrointestinal Surgery · 2002 · 33 citations

Stage Ii, Oncogenic Agent, Medicine +10